Altogether, these observations suggest that in some patients with T cell-driven HES, higher and/or more frequent dosing of anti-IL-5 may be required to neutralize the large amounts of IL-5 produced in vivo. This evidence concerns the gene IL5 and hypereosinophilic syndrome.